Xadago (safinamide)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Xadago (safinamide)

How to buy Xadago: You can order Xadago (safinamide) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Zambon
Disease Parkinson's Disease
Indication Parkinson's Disease
Mode of Action Monoamine Oxidase-B (MAO-B) inhibitor
Approval Status EMA approved (EU); FDA approved (USA)
Strength 50 mg, 100 mg

Who is safinamide for?

Xadago (safinamide) is indicated as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. An “off” episode is a time when a patient’s medications are not working well, causing an increase in Parkinson’s symptoms, such as tremor and difficulty walking [1].

Recommended dose

Complete information about Xadago (safinamide) dosage and administration can be found here: [2][3].
The standard dosage is:
  • Start dose: 50 mg once daily at the same time of day
  • After two weeks, the dose may be increased to 100 mg once daily, based on individual's need and tolerability
Do not exceed 50 mg once daily in patients with moderate hepatic impairment; this medicine is contraindicated in patients with severe hepatic impairment.
Consult your treating doctor for personalised dosing.

What is safinamide and how does it work?

Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor, indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes [2].
Parkinson’s disease develops when neurons (brain cells) in a particular part of the brain stop working properly and are lost over time. These neurons produce an important chemical called dopamine. Dopamine is used by the brain to send messages across brain areas to help control movement. Eventually, the brain cannot make enough dopamine to control the movement properly. There is currently no cure for Parkinson’s Disease. Existing treatments aim to help patients manage symptoms [4].
The active substance in Xadago — safinamide — blocks the enzyme MAO-B which breaks down dopamine, thereby helping to restore dopamine levels in the brain and improving the patient's symptoms [5].

What is safinamide's approval status?

Xadago (safinamide) was approved by:
  • FDA (USA) on March 21, 2017 [1]
  • EMA (EU) on February 24, 2017 [5]
as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
The approval of Xadago (safinamide) for Parkinson’s disease was based on two main studies involving a total of 1,218 patients with late stage Parkinson’s disease who experienced fluctuations in their status. In both studies, 6 months treatment with Xadago increased the time during the day during which patients were ‘on’ and able to move by 30 - 60 minutes when compared with placebo [5].
In study 1 (016), which lasted for 24 weeks, patients received either safinamide 50 mg/day (N = 217 patients), safinamide 100 mg/day (N=216 patients), or placebo (N= 212 patients). Patients on the placebo group had an average additional ‘on’ time of 0.5 ± 0.2 hours, compared to 1.0 ± 0.2 in patients on safinamide 50 mg, and 1.2 ± 0.2 in patients on safinamide 100 mg [2][3].
In study 2 (016/018), which lasted for 2 years, patients received either safinamide 50 mg/day (N = 223 patients), safinamide 100 mg/day (N=224 patients), or placebo (N= 222 patients). Patients on the placebo arm had an average additional ‘on’ time of 0.8 ± 0.2 hours, compared to 1.4 ± 0.2 in patients on safinamide 50 mg, and 1.5 ± 0.2 in patients on safinamide 100 mg [2][3].
Among the most common side effects with safinamide are insomnia, dyskinesia (difficulty controlling movement), somnolence, dizziness, and nausea [2][3]. Safinamide must not be used in patients with severe liver problems, in patients treated with pethidine or other MAO inhibiting medicines [2][3].
[1] FDA News Release: FDA approves drug to treat Parkinson’s disease, 21/03/2017.
[2] Summary of Product Characteristics [FDA]: Xadago (safinamide), US WorldMeds, LLC, Mar. 2017.
[3] Summary of Product Characteristics [EMA]: Xadago (safinamide), Zambon SpA, Apr. 2017.
[4] Parkinsons.UK, cited on 10/05/2017.
[5] EMA. Human Medicines: Xadago (safinamide), 30/03/2015 (last update: 5/04/2017), cited on 10/05/2017.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.